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Abstract
In 5–40% of respiratory infections in children, the diagnostics remain negative, suggesting that the patients might be
infected with a yet unknown pathogen. Virus discovery cDNA-AFLP (VIDISCA) is a virus discovery method based on
recognition of restriction enzyme cleavage sites, ligation of adaptors and subsequent amplification by PCR. However, direct
discovery of unknown pathogens in nasopharyngeal swabs is difficult due to the high concentration of ribosomal RNA
(rRNA) that acts as competitor. In the current study we optimized VIDISCA by adjusting the reverse transcription enzymes
and decreasing rRNA amplification in the reverse transcription, using hexamer oligonucleotides that do not anneal to rRNA.
Residual cDNA synthesis on rRNA templates was further reduced with oligonucleotides that anneal to rRNA but can not be
extended due to 39-dideoxy-C6-modification. With these modifications .90% reduction of rRNA amplification was
established. Further improvement of the VIDISCA sensitivity was obtained by high throughput sequencing (VIDISCA-454).
Eighteen nasopharyngeal swabs were analysed, all containing known respiratory viruses. We could identify the proper virus
in the majority of samples tested (11/18). The median load in the VIDISCA-454 positive samples was 7.2 E5 viral genome
copies/ml (ranging from 1.4 E3–7.7 E6). Our results show that optimization of VIDISCA and subsequent high-throughput-
sequencing enhances sensitivity drastically and provides the opportunity to perform virus discovery directly in patient
material.
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Introduction
Respiratory tract infection is the most common cause of
hospitalization of children below the age of 5 years [1,2]. In 5–
40% of these hospitalizations no infectious agent can be identified
but it is suspected that a viral infection is involved [3–5]. In these
cases a yet unknown virus might be the cause of respiratory illness.
In the last decades several viral discovery methods have been
developed which can detect viruses without knowledge of the
genome sequence. We have previously used virus discovery
cDNA-AFLP (VIDISCA) to discover the human coronavirus
NL63 (HCoV-NL63) [6] and we were the first to describe human
parechovirus type 5 and 6 in the Netherlands using the same
technique [7]. In the VIDISCA assay viral genomes (which are
(reverse-) transcribed into double stranded DNA) are digested with
restriction enzymes. The enzymes digest short (4 nucleotides)
recognition sequences that are present in virtually all viruses. After
ligation of adaptors, the digested fragments are PCR amplified
with adaptor-specific primers. The assay is user-friendly however
the sensitivity of the assay is low. At least 1 E6 genome copies/ml
of a virus in a background that is low in competitor RNA/DNA
are needed. These conditions are generally only met when virus
culture supernatant is used. In clinical respiratory samples like
nasopharyngeal swabs in universal transport medium (UTM)
various amounts of competitor RNA/DNA from disrupted cells/
bacteria can be present. Ribosomal RNA, which is ,80% of the
total cellular RNA, is one of the biggest problems due to its high
copy number and its stability within ribosomes. In particular RNA
viruses are difficult to discover since in these cases a reverse
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competiting nucleic acid sequences.
One research group has addressed the problem of competing
rRNA [8]. Endoh et al showed that reverse transcription with 96
hexamers that can not anneal to rRNA, decreases the amount of
background amplification and enhances the sensitivity of a virus
discovery assay. We evaluated the benefit of the non-rRNA-
hexamers in VIDISCA. Furthermore, we evaluated whether the
choice of the restriction enzyme can decrease rRNA amplification.
Finally, specific blocking of rRNA reverse transcription by rRNA
recognizing oligo’s that contain a 39 dideoxy-C6 modification
(which can not be extended), further inhibits cDNA synthesis of
the target. All three steps to decrease the effect of inhibitor rRNA
are presented in this paper. Furthermore we monitored the
performance of the optimized amplification in a high throughput
sequencing setting, by combining VIDISCA with Roche 454 GS
FLX Titanium sequencing.
Results
VIDISCA with decreased amplification of background
rRNA
Respiratory samples contain non-viral nucleic acids that
interfere in virus discovery techniques like VIDISCA. It is
relatively easy to decrease the influence of background bacterial
or human DNA and mRNA by centrifugation and DNase/RNase
treatment, but ribosomal RNA (rRNA) is difficult to eliminate
because the ribosomal proteins protect the rRNA inside the
ribosomes. Instead of degrading the competing rRNA, it is an
option to adjust the amplification procedure during VIDISCA,
such that rRNA amplification decreases. The method can be
adjusted at several levels: 1) non-rRNA-annealing-primers can be
used during reverse transcription 2) a choice for certain restriction
enzymes can be made to diminish the chance of rRNA digestion
and subsequent amplification, and 3) rRNA-blocking oligos can be
used during the reverse transcription to halt cDNA synthesis on an
rRNA template.
1) non-rRNA-hexamers in the reverse transcription
reaction. Endoh and colleagues designed a mix of 96
hexamers that do not or hardly target rRNA but can amplify all
known viruses by RT-PCR [8]. These non-rRNA-hexamers were
tested in VIDISCA by using a dilution range of human echovirus
18 culture supernatant (1 E8–1 E4 copies/ml), a virus harvest of
which we established that it contains competitor rRNA. The
cDNA was produced either with normal hexamers (containing the
4096 variants) or non-rRNA-hexamers. Viral sequences could be
detected in samples with a concentration of 1 E6 to 1 E8 viral
genomic RNA copies/ml (see in figure 1A) in case non-rRNA-
hexamers are used in the RT reaction, whereas the sample that
was treated with the normal random hexamers was only positive
in the highest concentration (1 E8 copies/ml). Moreover, 3
viral fragments were amplified in the non-rRNA-hexamer
amplification, whereas only 1 viral fragment was amplified with
the standard procedure (figure 1A). Figure 1B shows that the
Figure 1. Enhanced viral RNA amplification in VIDISCA using non-ribosomal hexamers during reverse transcription. VIDISCA
fragments are visualized on a 3% metaphor gel. A dilution series of echovirus 18 was used and the concentration per ml is indicated above each lane.
NC=negative PBS control, M=25 bp marker.(a) VIDISCA products were generated with primers Hinp-A/Mse-C. The viral fragments are 167 bp,
296 bp and 382 bp in size. (b) VIDISCA products amplified with primers Hinp-A/Mse-A. The product originating from rRNA (70 bp) is indicated by an
arrow.
doi:10.1371/journal.pone.0016118.g001
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amplification, since the PCR fragment that originates from rRNA
is notably reduced (arrow in figure 1B).
To quantify the inhibition of rRNA amplification we performed
various real-time PCRs targeting cDNA of 28S rRNA and 18S
rRNA using 2 nasopharyngeal swabs (I and II) as input. Both
samples contained high concentrations of rRNA. The samples
were reverse transcribed with either the complete set of hexamers
or the non-rRNA-hexamers. With non-rRNA-hexamers substan-
tially lower amounts of rRNA-derived cDNA was generated with
on average more than 1 log decrease, compared to the samples
treated with random hexamers (see table 1). We observed that the
decreased cDNA synthesis on the 3700-region of 28S rRNA and
1000-region of 18S rRNA was considerable (,3,5 Ct=1 log),
however, not as strong as the decrease at regions 40–110 and
1780–1880 of 28S rRNA (almost 2 log decrease, table 1).
Inspecting the non-rRNA-hexamers revealed that this phenome-
non can be explained by residual priming by the non-rRNA-
hexamers. Although the primers are designed to anneal not or
hardly to rRNA, some do perfectly match with human rRNA,
especially in the region 3800 to 4000 (position 3803, 3840, 4040),
and the same for 18S rRNA region 1100 till 1200 (position 1121,
1123, 1134, 1185, 1187, 1207). However, in the regions where we
show strong decrease in rRNA cDNA synthesis (40–110 128S
rRNA and 1780–1880 18S rRNA), non-rRNA-hexamer can not
anneal at the 39site at close vicinity (position 1613 and 2272
respectively). One might suggest expelling the 8 hexamers that
anneal at the abovementioned locations to further enhance the
benefit of non-rRNA cDNA synthesis. However, Endoh et al
designed the non-ribosomal hexamers such that amplification of
viruses is not hampered, therefore we recommend using all 96
Endoh-designed non-rRNA hexamers.
To check whether viral amplification is not hampered by using
the non-rRNA-hexamers for cDNA synthesis we performed real-
time PCRs on cDNA of HCoV-NL63, echovirus 18, and human
coxsackievirus A16 virus culture supernatant. In all cases the
cDNA synthesis with non-rRNA-hexamers occurs as efficient as
normal hexamers, as no difference in virus specific real time PCRs
was noted (Table 2). The same has been demonstrated by Endoh
et al for SARS-CoV and bovine PIV-3 control viruses [8].
2) non-rRNA targeting restriction enzymes during
digestion. The original VIDSICA method described in 2004 is
based on amplification after digestion with 2 restriction enzymes
(Hinp1-I and MseI) [6]. Investigation of human rRNAs revealed that
28S rRNA contains a very high number of Hinp1-I recognition sites
(85, see table 3), but relatively low frequency of MseI restriction sites.
The high frequency of HinP1-I digestion in 28S rRNA and the
generation of a massive amount of small digested fragments likely
interferes in the VIDISCA-ligation. VIDISCA can also be
performed with only one restriction enzyme, the only adaptation
needed is the addition of 2 different adaptors that both can ligate to
MseI digested fragments. We checked our hypothesis by digesting
coxsackievirus B4 culture supernatant with only MseI in comparison
to the Hinp1-I/MseI combination, and evaluated the efficiency of
viral genome amplification in a single PCR. We observed a strongly
reduced background amplification in case only MseI was used in
VIDISCA (Figure 2, dots all indicate viral fragments).
3) rRNA-blocking oligos in the reverse transcription
reaction. To improve the sensitivity of VIDISCA even further
we designed oligonucleotides to block amplification of ribosomal
RNA. These oligonucleotides were designed to anneal specifically
to 18S and 28S rRNA and contain a 39 dideoxy C6 amino
modification to inhibit the elongation and thus the amplification of
rRNA-derived cDNA. These so called rRNA-blocking oligo’s were
designed on the most prevalent rRNA sequences retrieved from
VIDISCA experiments with nasopharyngeal swabs. To test the
inhibitory capacity of the blocking oligo’s we performed VIDISCA
with a nasopharyngeal sample as input. Blocking oligo’s were
added during reverse transcriptase reaction, and inhibition was
observed when blocking oligo’s were added (indicated as arrow in
figure 3). Sequencing of the inhibited PCR products confirmed
that they were derived from rRNA indicating that the blocking
oligo’s can reduce the amplification of rRNA.
In addition we performed a real-time RT-PCR targeting 18S
and 28S rRNA. As input 2 nasopharyngeal samples were used
(same samples that were used with the non-rRNA annealing
hexamers). We monitored cDNA synthesis via real time PCRs at 3
regions of 28S rRNA and 1 region of 18S rRNA. The choice for
these regions to monitor the rRNA-cDNA reverse trancription
efficiency was based on the VIDISCA fragments of which we
know that they are generated in VIDISCA amplification. Three of
the 4 regions are targeted by the rRNA-blocking oligo’s. On
average a 50% reduction of rRNA amplification was noticed at the
regions that were targeted by the rRNA-blocking oligo’s (see
Table 1). Of note, the reduction was not visible in the fragment
that was not targeted by a blocker (1780–1880 of 28S rRNA),
Table 1. Decrease of cDNA synthesis on rRNA templates.
Decrease rRNA-cDNA synthesis with
non-rRNA-hexamers
a
Decrease rRNA-cDNA synthesis with
rRNA-blocking oligo’s
b Total decrease
c
Sample number: I I II I II
Region in rRNA
40–110 28S 97% 96% 66
d%3 6
d% 98% 98%
1780–1880 28S 98% 96% 7
e%0
e% 95% 96%
3700–3800 28S 81% 83% 30
f%3 9
f% 87% 90%
930–1050 18S 75% 84% 51
g%0
g% 88% 83%
aIn comparison to cDNA synthesis with all 4096 random hexamers.
bIn comparison to cDNA synthesis without rRNA-blocking oligo’s.
cIn comparison to cDNA synthesis with all 4096 random hexamers and without rRNA-blocking oligo’s.
dbinding region for blocking oligo 4-Morrna.
eno rRNA-blocking oligo directed to this 1780–1880-region of 28S rRNA was added.
fbinding region for blocking oligo 3-Morrna.
gbinding region for blocking oligo 1-Morrna.
doi:10.1371/journal.pone.0016118.t001
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sample II no diminished signal was observed at 18S rRNA 1000-
region. This sample had extremely high concentrations of rRNA
(Ct value 16), thus we investigated whether the rRNA-blocking
oligo’s would work better in this sample when higher concentra-
tions of the blockers were used. Indeed, with 25 mM and 50 mMa
decrease in signal was noted (36.9% decrease and 70.1% decrease,
respectively) indicating that in some samples a concentration of
10 mM might be suboptimal. However, to diminish the chance of
unspecific blocking of viral RNA, we prefer the 10 mM
concentration of rRNA-blocking oligo’s. With this concentration
we observed no decrease in cDNA synthesis on HCoV-NL63 and
coxsackievirus B4 (measured by real-time RT-PCR, (table 4) ).
VIDISCA combined with high throughput sequencing
In figure 1 it is shown that the sensitivity of VIDISCA reaches 1
E6 viral genome copies/ml. Although this is an improvement, this
detection limit might be too low to detect viruses directly in clinical
samples. The concentration of respiratory viruses in nasopharyn-
geal swabs is in the main below 1 E6 copies/ml, and we can
assume that a yet unknown virus will be present in similar
concentrations. Thus additional improvement of the VIDISCA-
sensitivity is needed. High throughput sequencing is a relatively
new method allowing millions of nucleotides to be sequenced in
only one run (pyrosequencing). One of these devices is the 454
FLX/Titanium system of Roche which can generate over
1.000.000 DNA fragments of approximately 500 nucleotides per
run. By generating thousands of clonal amplified sequences from a
single sample, a viral minority can be detected. The VIDISCA
technique can easily be adapted for 454-FLX sequencing
(VIDISCA-454 method). The anchors that are ligated to the
digested fragment can be designed to contain the ‘‘A’’ and ‘‘B’’
primer sequence that are needed for clonal amplification in an
emulsion PCR to be used as input for 454 FLX sequencing.
However, VIDISCA-454 only becomes cost-effective in case a
few thousand sequences are sufficient for virus detection, as one
454 plate can then be used to analyze 56 samples (roughly 200 J
per sample). In that view VIDISCA-454 benefits strongly from the
aforementioned reduction in rRNA amplification since fewer
sequences are needed to detect a viral sequence.
We monitored the efficiency of VIDISCA-454 in 18 nasopha-
ryngeal swabs that contain known viruses. Only one third of a 454
picotiterplate was used, to check whether indeed a few thousand
sequences are enough for virus detection. Samples were selected
randomly from a large sample set collected during the GRACE
study, a large EU financed study on acute cough and antibiotic use
in adults. The 18 samples were assigned positive via specific
diagnostic PCRs, but supplied to us double blind to ensure
unbiased sequence analyses. Each sample was processed with its
own identifier sequence that allows pooling during emulsion PCR.
VIDISCA-454 products were visualized on agarose gel and
fragments were cut from gel at different size regions (200–300,
300–500 and 500–700 bp). Samples were run on 1.3 regions of a 4
regions Picotiterplate for the 454 Titanium system (per region 14
MID tagged samples were pooled) and processed according to the
small volume emulsion PCR. In total 202.975 reads were
generated of which 4406 were viral (2.2%). In 11 out of 18
samples viral sequences could be identified which all matched with
the respiratory virus that was found in diagnostic PCRs (Table 5).
The frequency of viral sequences per sample ranged between
0.01% and 40.5% (Table 5). The median viral load in the
VIDISCA-454 positive samples was 7.2 E5 viral genome copies/
ml (ranging from 1.4 E3–7.6 E6 genome copies/ml). Detection
was correlated to input viral load since the very low load samples
remained negative in VIDISCA-454 (median viral genome
concentration in VIDISCA-negative samples 3.5 E3; range 6.0
E2–1.1 E5). For most VIDISCA-454 positive samples large
genome coverage was observed, see table 5.
Discussion
Nowadays molecular techniques are becoming the standard for
the discovery of new viruses. Some methods use a conserved
region for universal primer design, based on the known viral
genomes [9–11]. These methods are applicable to specific virus
families, but cannot be used for all viruses. Furthermore, some yet
unknown viruses could be too diverse and therefore remain
negative in these kind of detection techniques [7]. Sequence
independent amplification methods, such as VIDISCA and
random-PCR, can identify viral sequences without prior knowl-
edge of a viral genome. Unfortunately, the detection of unknown
viral pathogens in respiratory clinical material is difficult with these
sequence independent virus discovery methods because of low
viral load and high background nucleic acids in these samples.
During the last years sequence independent virus discovery
techniques were mostly used with virus culture supernatant, as
they contain high concentrations of viral genomes [6,12], or to
discover previously unknown DNA viruses [13–15]. So far no
study has been able to identify novel human respiratory RNA
viruses with sequence independent amplification techniques. Thus
Table 2. No decrease in viral genome amplification with
random hexamers versus non-ribosomal hexamers.
Virus Reverse transcription- primers Ct Values
HCoV-NL63 Random hexamers 22.31
Non-ribosomal hexamers 23.12
Echovirus 18 Random hexamers 14.84
Non-ribosomal hexamers 14.90
Coxsackievirus A16 Random hexamers 22.16
Non-ribosomal hexamers 20.56
doi:10.1371/journal.pone.0016118.t002
Table 3. Theoretical VIDISCA amplifiable fragments in human rRNA, and number of restriction sites.
rRNA HinP1I nr of recognition sites MseI nr of recognition sites HinP1I6MseI nr of fragments
a MseI6MseI nr of fragments
a
5.8 S rRNA 0 1 0 0
18 S rRNA 11 12 7 9
28 S rRNA 85 8 8 4
aonly fragments larger than 50 nt and smaller than 600 nt are counted.
doi:10.1371/journal.pone.0016118.t003
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have to be optimized to allow discovery without requiring a
culture amplification step.
In the current study we increased the sensitivity of VIDISCA by
1) reducing background rRNA amplification, and 2) by increasing
the number of sequences obtained from a sample. We managed to
unfavor rRNA amplification by adjusting the reverse transcription
step. Utilization of primers during cDNA synthesis that poorly
recognize rRNA, in combination with the addition of oligo’s that
halt cDNA synthesis on rRNA templates successfully decreased
interfering background amplification. Additionally, using a single
restriction enzyme with low numbers of recognition sites in 28S
rRNA provided further reduction of useless and interfering
amplification. Thus all steps increased the ratio of viral genome
versus rRNA amplifications, and the benefit was shown in
VIDISCA-high throughput sequencing of clinical samples con-
taining known viruses. In the majority of clinical samples the virus
was easily identified by VIDISCA-454 (11 of 18). In two cases even
an input of 140 and 190 genome copies of an adenovirus and
influenza A virus could be detected by VIDISCA-454. Ideally, old-
protocol VIDISCA-454 (two restriction enzymes, random hexa-
mers and no rRNA-blocking oligo’s) should have been compared
with optimized VIDISCA-454. However, this comparison is
regrettably not possible due to limitation of the respiratory clinical
specimens that we used. Thus we rely on all the reconstructions
and monitoring performed with normal VIDISCA.
As mentioned above, the use of one restriction enzyme (MseI)
diminished background rRNA amplification. There is one
additional advantage of single restriction enzyme usage. In the
traditional VIDISCA two restriction enzymes were combined
(MseI and HinP1-I) and only fragments that have one restriction
site on the 59 site and the other in the 39 site are amplified after
ligation. Such VIDISCA amplification is restricted in case one of
the two enzymes has few recognition sites, or when the position of
the sites is not optimal (too far or too close from each other). By
using only one restriction enzyme, large parts of the genome would
be divided in amplifiable products, provided that the fragment size
is between 50 and 600 bp. In case of single restriction enzyme
digestion, both anchors can potentially ligate to both MseI
generated sticky end but only AB or BA containing fragments
can be used for sequencing. This might give the suggestion that
50% of the VIDISCA products are ineffective as they contain the
Figure 3. rRNA-blocking oligo’s decrease rRNA-cDNA synthesis in VIDISCA. VIDISCA fragment of ribosomal RNA visualized on a 3%
metaphor gel. A nasopharyngeal washing was used as input for VIDISCA with or without blocking oligo’s. Lane 1 and 2 are without blocking oligo’s
whereas lane 3 and 4 are with blocking oligo’s, M=25 bp marker. The arrow indicates the rRNA fragment of which the amplification was decreased.
doi:10.1371/journal.pone.0016118.g003
Figure 2. Enhanced amplification of viral fragments using one
restriction enzyme in VIDISCA. Visualization of VIDISCA fragments
digested with HinP1-I+MseI or MseI alone. VIDISCA fragments are
visualized on a 1% agarose gel, which were generated after a single first
round PCR of 40 cycles. The dots indicate viral fragments which were
only visible with MseI digestion.
doi:10.1371/journal.pone.0016118.g002
VIDISCA-454, a Sensitive Virus Discovery Assay
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16118same adaptor (AA and BB). However, the fragments containing 2
different primers are preferentially amplified in the PCR, since an
AA or BB fragment has a disadvantage that 59 and 39 ends anneal
to each other which interferes with primer annealing. We
definitely observed the higher chance of amplification of several
genome segments when only one restriction site is used.
Remarkably high genome coverage was noted in several samples
(reaching .70% for the samples containing RSV and HCoV-
OC43), a coverage which could never be achieved in case two
restriction enzymes were used in amplifications.
Other groups have used high throughput sequencing for virus
discovery as well. In one paper the viral community in an
Antarctic lake was described [16]. Lopez-Bueno et al. collected
water in spring and late summer from a fresh water lake
(Limnopolar lake) in Antarctica and used high throughput
sequencing to study the viral community in a location hardly
visited by larger eukaryotes. For the first time a large amount of
sequence data was retrieved from this isolated place which led to
the identification of at least 12 viral families of which two are
claimed to represent new families. Their results show the
enormous possibilities for virus discovery and high throughput
sequencing. The authors also address a large amount of unknown
sequences present in their data set. We also observed the presence
of unknown sequences within our data set. It could be that these
sequences are derived from yet unknown viruses, or it could be
that the sequences are part of a genomic sequence from a known
organism, e.g. a bacterium of which not the complete genomic
sequence is present in the Genbank databases. Thus care should
be taken to assign sequences as potentially viral, since so many
organisms have not been fully sequenced.
There are several advantages of high throughput sequencing in
comparison to BigDye terminator sequencing. First of all, with
high throughput sequencing and pooling of samples that carry
their own recognition sequence the VIDISCA cost per sample is
reduced, since selective VIDISCA-PCR, metaphor agarose gel
visualization, purification of fragments from gel, TA cloning,
colony PCR and subsequent BigDye sequencing can all be
omitted. Secondly, the amount of sequence data received from a
single sample is higher than what can be achieved in standard
VIDSCA, thus increasing the chances of identifying an unknown
virus. This method opens new opportunities for virus discovery,
not only in respiratory samples of undiagnosed respiratory
infection, but also in diseases such as Amyotrophic lateral sclerosis
(ALS), Kawasaki disease (KD) and Multiple sclerosis (MS). For
these syndromes a viral pathogen has been suggested [17–19] but
could not be confirmed so far. With VIDISCA-454 it is now
possible to investigate samples from these patients for unknown
viruses.
Materials and Methods
Ethics Statement
Patients were randomly chosen from the large European EU-
financed GRACE study (https://www.grace-lrti.org). Ethics
review committees in each country approved the study, Cardiff
Table 4. No inhibition of viral genome amplification with
rRNA-blocking oligo’s.
Virus rRNA-blocking oligo’s Ct Values
HCoV-NL63 + 14.8
2 13.6
Coxsackievirus B4 + 18.5
2 19.0
doi:10.1371/journal.pone.0016118.t004
Table 5. Respiratory virus detection with VIDISCA-454.
Sample nr Respiratory virus Viral load copies/ml Result VIDISCA-454 Nr of reads Nr of viral reads % viral reads
% genome
coverage
A0211 Human PIV-1 1.2 E3 - 32671 0 ,0.003%
D0424 RSV 2.4 E4 - 3437 0 ,0.02%
E1573 Influenza B 6.1 E4 Influenza B 4262 2 0.04% 0.8%
A2829 Influenza A 8.9 E5 Influenza A 9924 14 0.14% 11%
E0061 HCoV-NL63 1.0 E4 HCoV-NL63 8641 3 0.03% 0.8%
I1647 RSV 3.3 E6 RSV 3497 167 4.8% 4%
I4335 Influenza B 1.5 E4 - 2283 0 ,0,04%
O1189 HRV 1.2 E5 - 4030 0 ,0.02%
E0117 Influenza A 6.0 E2 - 2449 0 ,0.04%
I0555 Adenovirus 1.4 E3 Adenovirus 13478 13 0.1% 4%
I2193 RSV 1.2 E6 RSV 16701 577 3.5% 71%
I4363 Influenza B 1.5 E6 Influenza B 15595 459 2.9% 30%
O2967 Influenza B 2.0 E5 Influenza B 8132 14 0.2% 11%
S2719 HCOV-OC43 7.6 E6 HCoV-OC43 7437 3014 40.5% 79%
B0702 HCoV-OC43 3.5 E3 - 10170 0 ,0.01%
F1308 Influenza A 1.4 E3 - 9556 0 ,0.01%
H1940 Influenza A 1.9 E3 Influenza A 8362 1 0.01% 0.3%
I3747 HCoV-OC43 7.2 E5 HCoV-OC43 11691 114 1.0% 22%
doi:10.1371/journal.pone.0016118.t005
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Hampshire Research Ethics Committee A; Utrecht (Netherlands)
Medisch Ethische Toetsingscommissie Universitair Medisch
Centrum Utrecht; Barcelona (Spain) Comite `e `tic d’investigacio ´
clı ´nica Hospital Clı ´nic de Barcelona; Mataro (Spain): Comite `
d’E `tica d’Investigacio ´ Clı ´nica (CEIC) del Consorci Sanitari del
Maresme; Rotenburg (Germany) Ethik-Kommission der Medizi-
nischen Fakulta ¨t der Georg-August-Universita ¨t Go ¨ttingen, An-
twerpen (Belgium): UZ Antwerpen Comite ´ voor Medische Ethiek;
Lodz, Szeczecin, and Bialystok (Poland): Komisja Bioetyki
Uniwersytetu Medycznego W Lodzi; Milano (Italy) IRCCS
Fondazione Ca ` Granda Policlinico; Jonkoping (Sweden): Regio-
nala etikpro ¨vningsna ¨mnden i Linko ¨ping; Bratislava (Slovakia):
Etika Komisia Bratislavskeho; Gent (Belgium): Ethisch Comite ´
Universitair Ziekenhuis Gent; Nice (France) Comite ´ de Protection
des Personnes Sud-Me ´diterrane ´e II, Ho ˆpital Salvator; Jesenice
(Slovenia): Komisija Republike Slovenije za Medicinsko Etiko.
Written informed consent was provided by all study participants.
Clinical samples and viruses
HCoV-NL63, echovirus 18, human coxsackievirus A16 and
human coxsackievirus B4 were cultured on an epithelial monkey
kidney cell line (LLC-MK2 [6]) in MEM Hank’s/Earle’s (2:1)
medium (Invitrogen) with 3% inactivated fetal bovine serum (FBS;
Cambrex Bio Science). Both media were supplemented with
penicillin (0.1 mg/ml) and streptomycin (0.1 mg/ml) (Duchefa
Biochemie). Viruses were harvested on day 2 except human
coronavirus NL63 (HCoV-NL63) which was harvested at day 7.
During the GRACE study, a large EU financed study on acute
cough and antibiotic use in adults consulting their general
practitioner, flocked nasopharyngeal swabs (Copan) in universal
transport medium (UTM) were collected from all patients. Eighteen
of these nasopharyngeal specimens were randomly selected (double
blind) and included in this study and proven positive by specific
diagnostic PCR’s for either human rhinovirus (HRV), respiratory
syncytial virus (RSV), human coronavirus OC43 (HCoV-OC43),
HCoV-NL63, Influenzavirus A, Influenzavirus B, parainfluenza-
virus 3 (PIV3) or adenovirus. The diagnostics for the respiratory
viruses were determined by in-house multiplex real-time PCR
assays [20–22], all primers and probes are available on request.
Viral loads were determined by virus-specific quantative real time
PCRs using standard curves based on plasmids containing the virus
sequence of interest (details available on request).
Real time RT-PCR for enterovirus, HCoV-NL63 and rRNA
Nucleid acids were extracted by Boom isolation [23]. Elution of
nucleic acids was performed in sterile H2Oo ri n1 0mM of rRNA-
blocking oligonucleotides (2 mM each, see below). The reverse
transcription was performed as described [6] with the adjustment
that in some cases 25 ng of random hexamers (Amersham
Biosciences) or non-ribosomal hexamers were used. Enterovirus
real-time PCR was performed to quantify the efficiency of
echovirus 18, human coxsackievirus A16 and human coxsackie-
virus B4 reverse transcription reactions, whereas a specific HCoV-
NL63 real time PCR was performed to quantify the HCoV-NL63
reverse transcription efficiency [24,25]. Ribosomal RNA real time
PCR was performed with the primers below, and the Quantifast
SYBR Green PCR kit (Qiagen). Real-time PCR with primerset 5/
6 was additionally run with a probe (rRNA28S_3674 59-FAM-
GGGTGTTGACGCGATGTGATTTCT-TAMRA-39) and the
platinum quantitative PCR Supermix-UDG system (Invitrogen).
1. rRNA28S_40F 59-TCAGATCAGACGTGGCGACCCG-
CTG-39
2. rRNA28S_110R 59-CGCTGGGCTCTTCCCTGTTCACT-
C-39
3. rRNA28S_1780F 59-TGGGTAAGAAGCCCGGCTCGCT-39
4. rRNA28S_1880R 59- TTCGGTTCATCCCGCAGCGC-
CAGTTC-39
5. rRNA28S_3647F 59- AAACAAAGCATCGCGAAGG-39
6.rRNA28S_3740R 59- CGCTTCATTGAATTTCTT-
CACTT-39
7. rRNA18S_930F 59-GACGGCCGGGGGCATTCGTATTG-39
8. rRNA18S_1050R 59- CGACGGTATCTGATCGTCTTC-
GAACC-39
VIDISCA
VIDISCA was performed as described with some adaptations
[6]. In short, cell debris and mitochondria were removed by
centrifugation and residual DNA was degraded with 20 U
TURBO
TM DNase (Ambion). Nucleic acid isolation was per-
formed as described by Boom et al.[23], elution in H2O with or
without 10 mM rRNA-blocking oligonucleotides:
N 1-Morrna 59 CTTTCGCTCTGGTCCGT 39 –C6 [18S, nt.
977–1071]
N 2-Morrna 59 CACTAATTAGATGACGAGG 39–C6 [28S,
nt. 3767–3785]
N 3-Morrna 59 TGACATTCAGAGCACTGG 39–C6 [28S, nt.
3679–3696]
N 4-Morrna 59 GTTACTGAGGGAATCCTG 39 –C6 [28S, nt.
72–89]
N 5-Morrna 59 CACCAGTTCTAAGTCGG 39–C6 [28S, nt.
3580–3596]
Reverse transcription was performed with 2.5 mg of random
hexamers (Amersham Biosciences) or 2.5 mg non-ribosomal hexa-
mers [8] and 200 U of Moloney murine leukemia virus reverse
transcriptase enzyme (Invitrogen). After the RT reaction, second
strand synthesis was performed with 5 U Klenow frament (39 -5 9
exo-) (Westburg) and 7.5 U of RNase H (Amersham) followed by a
phenol chloroform extraction and ethanol precipitation. The
digestion was performed for 2h at 37uCb y1 0Uo fHinP1-I (New
EnglandBiolabs)and 10UofMseI (NewEnglandBiolabs)restriction
enzymes or only by 10U of MseI (New England Biolabs). Ligation of
MSE and HINP anchors was performed as described [6]. In case of
single MseI digestiona 2
nd MSE anchor wasadded (MID1-top-A59-
GCCTCCCTCICGCCATCAGACGAGTGCGTA-39; MID1-
bottom-A 59-TATACGCACTCGTCTGATGGCGCGAGGGA-
GGC-39; Top-B 59- GCCTTGCCAGCCCGCTCAGA-39; Bot-
tom-B 59-TATCTGAGCGGGCTGGCAAGGC-39). The first
round of PCR amplification was performed with primers annealing
to the anchors and covers 20 cycles, or 45 cycles in case only a single
PCR was used. A second PCR was used to enhance the signal using
primers that are extended at the 39 with one nucleotide (either A, T,
C, or G) so a total of 16 primer combinations. PCR fragments were
visualized on 3% metaphor agarose gels (Cambrex), fragments of
interest were cut from gel, purified with NucleoSpinH Extract II
(Macherey-Nagel), cloned using TOPO TA cloning kit (Invitrogen)
and sequenced with BidDye terminator reagents (Applied Biosys-
tems). Data analysis was conducted with CodonCode Aligner
software and BLAST.
VIDISCA-454
VIDISCA was performed as described above with minor
changes (Figure 4). Reverse transcription was performed with
VIDISCA-454, a Sensitive Virus Discovery Assay
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ligase (5 U, Invitrogen). The anchor ligation was performed with
anchors, based on primer A with an identifier sequence (MIDs of
10 nt see GS FLX Shotgun DNA Library Preparation Method
Manual) and 1 anchor containing primer B. In total 14 different
identifier sequences were used, allowing 14 samples to be pooled.
Amplification in a single PCR was performed with 0.4 mMo f
primer A-MID (59- CGTATCGCCTCCCTCGCGCCATCAG -
39) and 0.4 mM of primer B (59- CTATGCGCCTTGC-
CAGCCCGCTCAG -39) with the following thermo-cycling
profile: 1 cycle of 94uC for 5 min, 40 cycles of 94uC for 60 s,
55uC for 60 s and 72uC for 2 min, and 1 cycle of 72uC for 10 min.
Of each sample 15 ml of product was loaded on a 1% agarose gel
and 3 size regions were cut from gel: 200–300 bp, 300–500 bp
and 500–700. Each size region was purified with NucleoSpinH
Extract II (Macherey-Nagel). DNA was quantified with the Quant-
iT
TM dsDNA Assay Kit on a Qubit fluorometer (Invitrogen).
Emulsion PCR was performed according to the suppliers protocol
Figure 4. Schematic overview of VIDISCA-454.
doi:10.1371/journal.pone.0016118.g004
VIDISCA-454, a Sensitive Virus Discovery Assay
PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16118(LIB-A SV emPCR kit, GS FLX Titanium PicoTiterPlate kit
(70675), GS FLX Titanium XLR 70 Sequencing kit (Roche)).
Each emulsion PCR amplifies fragments of 14 different samples.
Samples were run on a 4 regions Picotiterplate for the 454
Titanium system (per region 14 samples were run) and processed
according to the emulsion small volume PCR protocol with 2 E6
beads per emulsion as input and 4 small volume emulsions per
region (direct titration protocol). Sequence reads were assembled
using the CodonCode software (www.codoncode.com) and the
search for viral sequences was performed with the Blast tool of
Genbank.
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